Brand Name

ZYFLO

Generic Name
Zileuton
View Brand Information
FDA approval date: December 06, 1996
Classification: 5-Lipoxygenase Inhibitor
Form: Tablet

What is ZYFLO (Zileuton)?

ZYFLO is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

The dual role of leukotrienes in the tumor microenvironment: balancing pro-tumorigenic and anti-tumor immunity.
The dual role of leukotrienes in the tumor microenvironment: balancing pro-tumorigenic and anti-tumor immunity.
Journal: Cancer biology & therapy
Published: June 23, 2026
Editorial Note: Zileuton Improves Memory Deficits, Amyloid and Tau Pathology in a Mouse Model of Alzheimer's Disease with Plaques and Tangles.
Editorial Note: Zileuton Improves Memory Deficits, Amyloid and Tau Pathology in a Mouse Model of Alzheimer's Disease with Plaques and Tangles.
Journal: PloS one
Published: May 20, 2026
Synthetic heterocyclic scaffolds relevant to human 15-lipoxygenase-2 (h15-LOX-2) inhibition: Scaffold diversity, structure-activity relationships, selectivity challenges, and future directions.
Synthetic heterocyclic scaffolds relevant to human 15-lipoxygenase-2 (h15-LOX-2) inhibition: Scaffold diversity, structure-activity relationships, selectivity challenges, and future directions.
Journal: European journal of medicinal chemistry
Published: May 03, 2026
View All Latest Advances